Background
Methods
Type of review
Eligibility criteria
Information sources
Search
Study selection
Data collection process
Data items
Risk of bias in individual studies
Results
Reliability
Summary of trials
Variable | Level | Number of articles |
---|---|---|
Type of article (n) | Results of primary analysis of clinical trial | 228 (97.4%) |
Design / protocol of clinical trial | 3 (1.3%) | |
Results of secondary analysis of clinical trial | 3 (1.3%) | |
Year (n) | 2000–2004 | 47 (20.0%) |
2005–2009 | 85 (36.3%) | |
2010–2015 | 102 (43.6%) | |
Country of origin (n) | USA | 101 (43.2%) |
UK | 39 (16.7%) | |
Netherlands | 19 (8.1%) | |
Canada | 14 (6.0%) | |
Australia | 11 (4.7%) | |
Other | 50 (21.4%) | |
Target population (n) | Adult patients | 172 (73.5%) |
Children / adolescent patients | 45 (19.2%) | |
People at risk | 5 (2.1%) | |
Workers | 12 (5.1%) | |
Target condition (n) | Depression | 30 (28.6%) |
Substance abuse | 18 (17.1%) | |
Psychosis | 14 (13.3%) | |
Neurodegeneration | 13 (12.4%) | |
Anxiety | 6 (5.7%) | |
Attention deficit hyperactivity disorder | 5 (4.8%) | |
Others | 19 (18.1%) | |
Intervention (n) | Cognitive behavioural therapy / CBT skills | 33 (14.1%) |
Care management / interdisciplinary care | 26 (11.1%) | |
Education | 21 (9.0%) | |
Motivational interviewing / motivational enhancement therapy | 19 (8.1%) | |
Other psychotherapy / counselling | 16 (6.8%) | |
Assessment and feedback | 8 (3.4%) | |
Parenting interventions | 8 (3.4%) | |
Others | 103 (44.0%) | |
Phase (n) | Early (pilot and feasibility trials) | 29 (12.4%) |
Late | 205 (87.6%) | |
Level of treatment allocation (n) | Participant level | 141 (60.3%) |
Cluster level | 93 (39.7%) | |
Sample size (median; IQR) | Participant-level allocation | 143 (84–261) |
Cluster-level allocation | 285 (158–579) | |
Cluster size in cRCTs (median; range) | 10 (3–200) |
Summary of assessment of bias
Variable | Level | Trials with individual-level randomisation (n) | Trials with cluster randomisation (n) |
---|---|---|---|
Jadad score (possible range of 0–5; higher scores indicate lower likelihood of bias) | 0 | 2 (1.4%) | 1 (1.1%) |
1 | 26 (18.8%) | 22 (23.9%) | |
2 | 44 (31.9%) | 32 (34.8%) | |
3 | 66 (47.8%) | 37 (40.2%) | |
Allocation sequence adequately generated | Low risk | 75 (53.2%) | 44 (47.3%) |
High risk | 3 (2.1%) | 1 (1.1%) | |
Unclear | 63 (44.7%) | 48 (51.6%) | |
Allocation sequence adequately concealed | Low risk | 30 (21.3%) | 18 (19.3%) |
High risk | 3 (2.1%) | 1 (1.1%) | |
Unclear | 108 (76.6%) | 74 (79.6%) | |
Randomisation after consent obtained | Low risk | 116 (82.3%) | 23 (24.7%) |
High risk | 6 (4.3%) | 39 (41.9%) | |
Unclear / NA | 19 (13.5%) | 31 (33.3%) | |
Randomisation after baseline measures were completed | Low risk | 56 (39.7%) | 15 (16.1%) |
High risk | 14 (9.9%) | 41 (44.1%) | |
Unclear | 71 (50.4) | 37 (39.8%) | |
Baseline outcome measurements similar across trial arms | Low risk | 109 (77.3%) | 70 (75.3%) |
High risk | 9 (6.4%) | 11 (11.8%) | |
Unclear / NA | 23 (16.3%) | 12 (12.9%) | |
Baseline demographic characteristics similar across trial arms | Low risk | 121 (85.8%) | 69 (74.2%) |
High risk | 3 (2.1%) | 18 (19.4%) | |
Unclear / NA | 17 (12.1%) | 6 (6.5%) | |
Knowledge of allocation adequately concealed | Low risk | 0 (0%) | 0 (0%) |
High risk | 141 (100%) | 93 (100%) | |
Blinded outcome assessment | Low risk | 63 (44.7%) | 29 (31.2%) |
High risk | 8 (5.7%) | 17 (18.3%) | |
Unclear / NA | 70 (49.6%) | 47 (50.5%) | |
Incomplete outcome data | Low risk | 35 (24.8%) | 22 (23.7%) |
High risk | 82 (58.2%) | 57 (61.3) | |
Unclear / NA | 24 (17.0%) | 14 (15.1%) | |
Similar attrition between trial arms | Low risk | 85 (60.3%) | 51 (54.8%) |
High risk | 30 (21.3%) | 25 (26.9%) | |
Unclear / NA | 26 (18.4%) | 17 (18.3%) |
Processes driving contamination
Quantity of contamination
Reference | Control treatment | Active intervention | Measure of contamination | Contamination (control participants receiving intervention) |
---|---|---|---|---|
Aveyard et al. [40] | Basic behavioural support for smoking cessation | Behavioural support for smoking cessation | Nurse visit (1st extra); Telephone call; Nurse visit (2nd extra) | 12/469 (3%) 12/469 (3%) 5/469 (1%) |
Barton et al. [41] | No treatment | Mammography education (pamphlet and videotape) focusing on anxiety | Patient recall of: Pamphlet; Videotape | 9% 1% |
Bernstein et al. [42] | No treatment | Cognitive behavioural therapy | Service Questionnaire of anxiety treatment | 0/24 (0%) |
Borland et al. [43] | Minimal information | Behavioural support | Patients reporting use of extensive behavioural support | 45/378 (12%) |
Clarkson et al. [36] | Routine care | Self-efficacy education | Participants reporting use of electric toothbrush | 9/113 (8%)p 9/180 (5%)c |
Courneya et al. [44] | Group psychotherapy | Group psychotherapy and exercise programme | Patient-reported exercise | 10/45 (22%) |
Dilley et al. [45] | Usual care | Cognitive counselling | Patient-reported receipt of counselling | 45/158 (29%) |
Forchuk et al. [46] | Usual care | Transitional discharge from hospital | Patient-reported receipt of peer support and staff contact | 27% |
Heirich & Sieck [47] | Health education | Proactive follow-up counselling | Patients requesting personal counselling | 56% |
Johnson et al. [20] | Usual treatment | Clinical training in dual diagnosis of psychosis and substance misuse | Patients not taken on by trained case manager | 19/105 (18%) |
Khumalo-Sakutukwa et al. [48] | Standard HIV voluntary counselling and testing | HIV counselling, testing and self-management | Participants seeking out treatment from intervention centres | 1% |
Lamers et al. [49] | Usual care | Nurse-led minimal psychological intervention (MPI) | Patients who reported knowledge of MPI | 9/178 (5%) |
Lee & Gayp [37] | Attention control | Sleep hygiene package | Patient-reported use of: Bassinet; White noise device; Low lighting | 33/46 (72%)p 47/75 (62%)c 11/75 (14%)c 27/75 (36%)c |
Merritt et al. [50] | No intervention | Postcards with information about depression | Patients reporting having seen the postcards | 7/78 (1%) |
Moadel et al. [51] | Standard care | Smoking cessation group support and encouragement | Patients reporting discussion of active intervention patients; Patients reporting familiarity with program’s strategies | 6% 17% |
Mohr et al. [52] | Treatment as usual | Cognitive behavioural therapy | Patients who had contact with non-study therapist | 18/44 (41%) |
Phillips et al. [53] | Routine public health practice | Community engagement in healthy eating | Participants reporting participation in intervention programme | 1% |
Saitz et al. [54] | Usual care | Chronic care management (multidisciplinary care coordination; motivational therapy; counselling) | Patients who received a session of motivational enhancement therapy | 9/281 (3%) |
Shemilt et al. [55] | No funding for breakfast club | Funding for school-based breakfast club | School pupils with school breakfast club | 77% |
Stewart-Brown et al. [56] | No intervention | Incredible Years (parenting techniques) training | Participants attending community-based parenting programme | 4/44 (9%) |
Waghorn et al. [57] | Enhanced routine mental health case management | Supported employment and specialist illness management | Patients opting to transfer to intervention after 6 months | 28/102 (27%) |
Walpole et al. [58] | Social skills training | Motivational interviewing (MI) | Patients whose treatment was MI adherent | 37% |
Wells et al. [59] | Usual care | Quality improvement therapy (CBT) and medications (assessment and education) | Receipt of speciality counselling within 6 months | 13% |
Solutions used to counter contamination
Process driving contamination | Trial conduct solution | Number of papers |
---|---|---|
Clinicians deliver both active and control treatments | Recruiting groups of clinicians, each one of which is responsible for a single treatment | 16 |
Monitoring contamination using supervision/therapy session recordings | 10 | |
Formalising differences between interventions, e.g. using structured manual during therapist training | 6 | |
Asking clinicians not to use intervention content when treating those in control arm | 3 | |
Providing active intervention within the research project rather than health service | 1 | |
Using a script for contact with control participants during treatment | 1 | |
Clinicians not involved in active intervention treating participants in both trial arms | Blinding usual care clinicians | 4 |
Confining intervention to provision by specialist clinicians | 2 | |
Communication between clinicians in different trial arms | Asking clinicians not to share details of the intervention with each other | 5 |
Communication between participants in different trial arms | Holding treatment sessions at different times / in different locations | 13 |
Staggering the scheduling of data collection appointments / reducing waiting time so that participants do not meet in waiting room | 3 | |
Allocating separate therapists / modes of delivery for individual and group therapies when usual group therapy was shared by participants in both arms | 2 | |
Asking participants not to share contents of intervention with others | 2 | |
Excluding potential participants who know someone else attending screening | 2 | |
Holding separate sessions of existing group treatments for participants in separate trial arms in order to prevent contact | 1 | |
Restricting the release of intervention materials in order to reduce the chance of their being shared with control participants | 1 | |
Recruiting participants in blocks and providing one treatment at a time, with no new participants recruited during the final week of each period in order to maintain separation between trial arms | 1 | |
Participants switching clinicians and therefore trial arms | Preventing referrals for add-on care by clinicians who are members of study team | 1 |
Avoiding transfer of participants between clinicians | 1 | |
Participants seeking treatment outside the trial | Informing participants only about the treatment they were allocated to receive (Zelen’s design) | 8 |
Promising the intervention to control participants at the end of follow-up | 2 | |
Active treatment is available to some extent within the healthcare system | Making intervention distinct from usual care by adapting one or other | 2 |
Establishing common treatment for all participants | 1 | |
Excluding institutions that already offer some aspect of the intervention | 1 |